Skip to main content

Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis

Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following successful bridging study Topline data anticipated in the second half of 2028, approximately one year earlier than previously expected; Entera commits to a 12-month extension study to run in parallel with potential NDA review TEL AVIV, March 04, 2026 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptide and protein replacement therapies, today announced the submission to the U.S. Food and Drug Administration (FDA) of a clinical amendment providing a streamlined Phase 3 protocol, statistical analysis plan (SAP),...

Continue reading

CDT Positions for Transformational Growth

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 04, 2026 (GLOBE NEWSWIRE) — CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) advances multiple initiatives designed to enhance shareholder value and expand its strategic footprint. The Company continues to actively develop and expand its pharmaceutical asset portfolio, including solid-form and cocrystal development programs, alongside its licensed clinical assets AZD1656, AZD5658 and AZD5904 under its agreement with AstraZeneca. CDT remains engaged in ongoing evaluation and out-licensing discussions and continues to assess pathways to maximize the commercial and strategic potential of these assets. The Company believes this diversified asset base provides several avenues through which value may be realized. In addition, CDT recently completed its strategic acquisition of a...

Continue reading

Lakeland Fire + Safety’s Arizona PPE Provides Support to the Phoenix Fire Department for the 10th Consecutive Year

Ongoing Service Highlights a Decade of Exceptional Quality, Support and Trust HUNTSVILLE, Ala., March 04, 2026 (GLOBE NEWSWIRE) — Lakeland Industries, Inc. (“Lakeland Fire + Safety” or “Lakeland”) (NASDAQ: LAKE), a leading global manufacturer of protective clothing and apparel for industry, healthcare and first responders, today announced that its Arizona PPE Recon, Inc. (“Arizona PPE”) subsidiary, which specializes in personal protective equipment (PPE) care and maintenance services, has marked a milestone with the City of Phoenix, Arizona Fire Department (“Phoenix Fire Dept.”) for ongoing PPE advanced decontamination, inspection and repair services for the 10th consecutive year. The Phoenix Fire Dept. employs over 1,900 sworn firefighters and more than 400 civilian personnel. As one of the busiest departments...

Continue reading

Olenox Industries Shares Positive Field Reports as Production Stabilizes

Wichita County, Texas, field expected to quickly meet or exceed BOE/day target CONROE, Texas, March 04, 2026 (GLOBE NEWSWIRE) — via IBN — Olenox Industries Inc. (NASDAQ: OLOX) (“Olenox” or the “Company”), a multifaceted energy company, today announces the Company’s well revitalization efforts are achieving success and hitting production targets. Going forward, the Company plans to bring additional wells into production on a weekly basis. Since December 2025, the Company has successfully revitalized 10 wells, with 25 more expected to be online by the end of the first quarter. Olenox deployed a dedicated rig in its Wichita field in December 2025, and the Company is pleased with the results in the few months since deployment, according to Olenox CEO Michael McLaren. “We are pleased with the progress of our workovers and revitalization...

Continue reading

Autonomix Medical Selected as Top Abstract at CRT 2026 and Selected for Podium Presentation of Clinical Feasibility and Outcomes of Novel Technique for Transvascular Peripheral RF Nerve Neurolysis

THE WOODLANDS, TX, March 04, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Nikola Cesarovic, PhD, will present clinical feasibility and outcome data at the Cardiovascular Research Technologies (CRT) 2026 Meeting, happening March 7-10, 2026, in Washington, DC. The abstract titled, “Novel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes,” will be presented during the Top Abstract Session (S194) on Saturday, March 7 from 2:18 – 2:24p ET for Hypertension Therapies and Renal Denervation session. Dr. Cesarovic will deliver a six-minute presentation, highlighting clinical feasibility and early outcomes...

Continue reading

Ypsilanti Deploys Beam Global Resilient Energy Products to Counter Grid Interruptions Amid Rising Oil Prices and Energy Volatility

SAN DIEGO, March 04, 2026 (GLOBE NEWSWIRE) — Beam Global (Nasdaq: BEEM), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation, energy security and smart city infrastructure today announced the deployment of off-grid, solar-powered EV ARC™ charging systems at the Ypsilanti Performance Space in Ypsilanti, Michigan. The deployment follows multi-day neighborhood power outages that highlighted the limitations of traditional grid-tied chargers, which shut down when the grid fails. Beam Global’s systems operate independently of the utility grid, generating and storing their own electricity and continuing to provide charging and vital electricity for first responders or others during utility grid outages. The project comes amid rising oil price volatility driven by geopolitical...

Continue reading

Viewbix Announces the Closing of Strategic Acquisition of Quantum X Labs – An Emerging Leader of Quantum Technologies

The acquisition encompasses Quantum’s proprietary intellectual property portfolio, including an innovative patent for AI-Quantum Error Correction Tel Aviv, Israel, March 04, 2026 (GLOBE NEWSWIRE) — Viewbix Inc. (Nasdaq: VBIX) (“Viewbix” or the “Company”), an advanced technologies company, today announced that it has completed the acquisition of 100% of Quantum X Labs Ltd. (“Quantum”), a multi-disciplinary quantum technology hub focused on quantum algorithms, navigation, and atomic clocks, pursuant to the definitive share purchase agreement dated December 15, 2025 (the “Agreement Date”). The acquisition encompasses Quantum’s proprietary intellectual property portfolio, including an innovative patent for AI-Quantum Error Correction. Quantum operates portfolio companies developing innovative solutions in quantum-based navigation (including...

Continue reading

ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP

Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales. Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel (a subsidiary of Pfizer Inc., NYSE: PFE). In that role, she was responsible for developing and executing strategy, building and developing teams, and driving overall business performance in the...

Continue reading

Decent Holding Inc. Reports FY2025 Financial Results

YANTAI, China, March 04, 2026 (GLOBE NEWSWIRE) — Decent Holding Inc. (Nasdaq: DXST) (“Decent“ or the ”Company“), an established wastewater treatment services provider in China, today announced its financial results for the fiscal year ended October 31, 2025. Fiscal Year 2025 Financial HighlightsTotal revenue for fiscal year 2025 increased by 12.2% to US$12.9 million, from US$11.5 million for fiscal year 2024. Revenue from wastewater treatment service increased by 68.7% to US$4.2 million from US$2.5 million in the prior fiscal year, primarily due to the completion of a wastewater treatment project during fiscal year 2025. Gross profit for fiscal year 2025 grew by 5.42% to $3.4 million, even though the gross profit margin declined to 26.1% from 27.8% in the prior year.Mr. Dingxin Sun, Chairman of the Company, commented: “Fiscal...

Continue reading

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ETEnrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027. OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the second quarter 2027 in advance of the BLA submission. OCU410 positive preliminary Phase 2 data announced in January. Full Phase 2 data expected in March 2026. First regional licensing agreement for OCU400 in 2025 initiates strategic partnership strategy ahead of commercialization Rounded out executive leadership team with top talent in business...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.